Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
savings account payday loans
Popular Articles

Men More Likely To Die From Cancer Than Women In UK
Men are 40 per cent more likely to die of cancer than women, and 16 per cent more likely to get it in the first place, said a report released Monday

Insurers Underpaid 'Billions' In Health Claims
The Senate Commerce Committee has found that a flawed payment database produced by a UnitedHealth subsidiary and distributed to other major insurance companies has led insurers to underpay millions of out-of-network claims, forcing patients to make up the difference of health care providers" fees, the Wall Street Journal reports. Aetna, Cigna, WellPoint, and other large insurers used the data to calculate their "reasonable and customary" charges. They also provided UnitedHealth"s subsidiary, Ingenix, with historic data about their payments, which became the foundation of ongoing versions of the flawed payment models.
News of the day
ADPH Designates USA Medical Center As Level I Trauma Center
The Alabama Department of Public Health has designated the University of South Alabama
Cardiovascular

Diabetes Drug Shows MS Potential

A small trial testing the benefits in multiple sclerosis (MS) of a drug used to treat type II diabetes, in combination with beta-interferon-1a, has been shown to potentially prevent brain cell loss. The results of the trial in 21 people investigating the effects of pioglitazone (also known as Actos) were published last month in the Journal of Neuroimmunology. Although the results of the trial showed some evidence of less damage in the brains of people with MS, there were too few people in the study to determine whether this effect was real. Dr. Susan Kohlhaas, Research Communications Officer at the MS Society said, "These results suggest that pioglitazone may have some benefit in combination with beta-interferon for people with relapsing remitting MS, but this trial is not large enough to determine exactly what that benefit will be. She added, "A larger clinical trial is needed to decide whether or not pioglitazone will be of benefit to people with MS." Multiple Sclerosis Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009